ProMIS Neurosciences, Inc. (PMN)
3.14
-0.07
(-2.18%)
USD |
NASDAQ |
Nov 18, 15:19
ProMIS Neurosciences Enterprise Value : -15.32M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -15.32M |
| November 16, 2026 | -14.42M |
| November 13, 2026 | -14.60M |
| November 12, 2026 | -12.89M |
| November 11, 2026 | -10.38M |
| November 10, 2026 | -8.41M |
| November 09, 2026 | -7.782M |
| November 06, 2026 | -6.796M |
| November 05, 2026 | -11.37M |
| November 04, 2026 | -12.54M |
| November 03, 2026 | -13.52M |
| November 02, 2026 | -17.20M |
| October 30, 2026 | -14.42M |
| October 29, 2026 | 55.27M |
| October 28, 2026 | 55.18M |
| October 27, 2026 | 42.71M |
| October 26, 2026 | 28.18M |
| October 23, 2026 | 30.70M |
| October 22, 2026 | 36.44M |
| October 21, 2026 | 37.78M |
| October 20, 2026 | 28.45M |
| October 19, 2026 | 29.71M |
| October 16, 2026 | 28.99M |
| October 15, 2026 | 33.92M |
| October 14, 2026 | 30.20M |
| Date | Value |
|---|---|
| October 13, 2026 | 33.57M |
| October 12, 2026 | 40.65M |
| October 09, 2026 | 42.09M |
| October 08, 2026 | 37.96M |
| October 07, 2026 | 37.69M |
| October 06, 2026 | 38.50M |
| October 05, 2026 | 39.93M |
| October 02, 2026 | 40.20M |
| October 01, 2026 | 40.02M |
| September 30, 2026 | 53.21M |
| September 29, 2026 | 41.91M |
| September 28, 2026 | 42.04M |
| September 25, 2026 | 47.60M |
| September 24, 2026 | 50.29M |
| September 23, 2026 | 62.58M |
| September 22, 2026 | 68.32M |
| September 21, 2026 | 68.77M |
| September 18, 2026 | 72.17M |
| September 17, 2026 | 67.24M |
| September 16, 2026 | 62.04M |
| September 15, 2026 | 62.13M |
| September 14, 2026 | 65.45M |
| September 11, 2026 | 68.14M |
| September 10, 2026 | 66.70M |
| September 09, 2026 | 75.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 16.96M |
| Oncolytics Biotech, Inc. | 48.55M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.758B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.162M |
| Total Expenses (Quarterly) | 8.162M |
| EPS Diluted (Quarterly) | -0.8927 |
| Earnings Yield | -267.4% |
| Normalized Earnings Yield | -267.50 |